Background: Egypt is one of the highest hepatitis C virus (HCV) endemic areas. Chronic
HCV infection has extra-hepatic manifestations, including non-Hodgkin lymphoma (NHL). Diffuse
large B-cell lymphoma (DLBCL) is commonly associated with HCV infection. The prognostic value
of HCV infection and HCV treatment in patients with DLBCL remains unclear until now.
Objective: The aim of our study is to evaluate the impact of HCV infection and HCV treatment as
independent prognostic factors on the event-free survival (EFS) and overall survival (OS) in Egyptian
patients with HCV associated DLBCL.
Methods: This study included 353 patients with DLBCL, collected retrospectively. While 34 patients
with HCV who received HCV antiviral therapy were collected prospectively. Patient’s characteristics
were collected from the patient records at the time of diagnosis. The status of the patients
about HCV infection and HCV treatment were also recorded. Disease progression, relapse, retreatment
or deaths were also verified through medical records. EFS and OS were calculated.
Results: EFS and OS significantly decrease in HCV infected and HCV non-treated patients when
compared with HCV non-infected and HCV treated patients, respectively. HCV infection but not
HCV treatment was independently associated with EFS and OS using univariate and multivariate
Conclusion: Hepatitis C virus infection is an independent prognostic factor for EFS and OS in diffuse
large B-cell lymphoma. HCV treatment is associated with higher EFS and OS but can not be
considered as an independent prognostic factor.